BiotechTube
vivoVerse

vivoVerse

San Francisco, United States· Est.
vivoverse.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

vivoVerse is an early-stage biotech company commercializing an AI-powered, whole-organism screening platform for toxicology and safety assessment. Its core technology, originating from academic research at The University of Texas at Austin, combines patented microfluidic chips (vivoChip), automated hardware (vivoScreen), and AI-driven image analysis to run high-throughput assays using C. elegans. The company's initial focus is on the vivoDART assay for developmental and reproductive toxicity, claiming it is 15x faster and 50x lower cost than mammalian assays, targeting industries like agrichemicals, pharmaceuticals, and petrochemicals to reduce animal testing and accelerate compound prioritization.

Toxicology

Technology Platform

vivoScreen® automated platform combining patented vivoChip® microfluidics for C. elegans handling, high-throughput imaging, and AI/ML for multiparametric whole-organism phenotypic analysis.

Opportunities

Strong regulatory and societal push for animal-free testing (3Rs) creates a receptive market.
The platform's claimed 15x speed and 50x cost advantage offers a compelling value proposition for R-intensive industries.
The technology is adaptable to multiple toxicological endpoints and potentially other discovery applications, allowing for portfolio expansion.

Risk Factors

Regulatory acceptance of the C.
elegans model for safety decision-making is uncertain and a lengthy process.
Competition from other alternative testing methods and established practices presents adoption hurdles.
As an early-stage company, it faces execution risks in scaling sales, manufacturing, and assay development with limited resources.

Competitive Landscape

vivoVerse competes in the alternative toxicology testing market against established in vitro cell-based assays, other organism-based models (e.g., zebrafish), organ-on-a-chip technologies, and computational toxicology (in silico) platforms. Its differentiation lies in the combination of whole-organism complexity, high-throughput automation, and AI-driven analysis. Key competitors include larger life science tools companies and specialized toxicology CROs offering similar screening services.

More companies in AI / Machine Learning →More companies in United States →